Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ1,38
KB-0,91
PKN94,995,51,62
Msft0,78
IBM-0,65
DCX70,5370,55-0,55
PFE-0,69
21.2.2018 0:25:23
Indexy online
AD Index online
select
AD Index online
 

  • 20.2.2018 19:49:20
Novo Nordisk -B- (Frankfurt)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
41,83 1,84 0,76 256 744
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 21.2.2018
Popis společnosti
Obecné informace
Název společnostiNovo Nordisk A/S
TickerNOVO B
Kmenové akcie:Ordinary Shares Class B
Kmenové akcie:Ordinary Shares Class A
RICNOVOb.CO
ISINDK0060534915
Poslední známé roční výsledky31.12.2017
Poslední známé čtvrtletní výsledky31.12.2017
Počet zaměstnanců k 31.12.2017 42 076
Akcie v oběhu k 31.12.20172 444 000 000
MěnaDKK
Kontaktní informace
UliceNovo Alle
MěstoBAGSVAERD
PSČ2880
ZeměDenmark
Kontatní osobaPeter Hugreffe Ankersen
Funkce kontaktní osobyCorporate Vice President & Head of Investor Relations
Telefon4 544 448 888
Fax4544436633

Business Summary: Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2017, Novo Nordisk A/S revenues decreased less than 1% to DKR111.7B. Net income increased 1% to DKR38.13B. Revenues reflect Diabetes Care segment increase of 4% to DKR92.88B, Europe segment increase of 2% to DKR21.19B, Region China segment increase of 2% to DKR10.71B, also reflect Biopharmaceuticals segment decrease of 18% to DKR18.82B.
Odvětvová klasifikace
TRBC2012Pharmaceuticals - NEC
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSMedicinal and Botanical Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICMedicinals And Botanicals
SICCommercial Physical Research



  • Poslední aktualizace: 21.2.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Representative DirectorMasami Iijima661.4.2015
President, Representative DirectorTatsuo Yasunaga5619.6.20151.4.2013
Chief Financial Officer, Senior Managing Executive Officer, Representative DirectorKeigo Matsubara621.4.20171.4.2012
Managing Executive Officer, Director of FinanceTakakazu Uchida571.4.20171.4.2014
Executive Officer, Director of FinanceYoshimitsu Gushiken-1.4.20181.4.2018
Executive Vice President, Chief Administrative Officer, Chief Information Officer, Chief Privacy Officer, Representative DirectoSatoshi Tanaka5921.6.20171.4.2011
Executive Vice President, Chief Compliance Officer, Representative DirectorMakoto Suzuki591.4.20171.4.2011
Executive Vice President, Representative DirectorYoshihiro Hombo601.4.20171.4.2010
Executive Vice President, Representative DirectorHiroyuki Kato611.4.20171.4.2010
Senior Managing Executive Officer, Representative DirectorShinsuke Fujii591.4.20171.4.2013